Willingdon Wealth Management’s GSK GSK Stock Holding History

Willingdon Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-87	Closed	-$5K	–	330
2019 Q4	$5K	Buy	87 +69	+383%	+$3.84K	﹤0.01%	276
2019 Q3	$1K	Hold	18	–	–	﹤0.01%	416
2019 Q2	$1K	Hold	18	–	–	﹤0.01%	292
2019 Q1	$1K	Hold	18	–	–	﹤0.01%	335
2018 Q4	$1K	Sell	18 -102	-85%	-$5.02K	﹤0.01%	320
2018 Q3	$6K	Buy	120 +102	+567%	+$5.18K	﹤0.01%	322
2018 Q2	$1K	Sell	18 -120	-87%	-$6.04K	﹤0.01%	313
2018 Q1	$7K	Sell	138 -94	-41%	-$4.38K	﹤0.01%	281
2017 Q4	$10K	Buy	232 +214	+1,189%	+$9.89K	﹤0.01%	246
2017 Q3	$1K	Buy	+18	New	+$913	﹤0.01%	289
2015 Q3	–	Sell	-20,748	Closed	-$1.08M	–	77
2015 Q2	$1.08M	Sell	20,748 -626	-3%	-$35.2K	1.04%	47
2015 Q1	$1.23M	Sell	21,374 -3,700	-15%	-$212K	1.02%	45
2014 Q4	$1.34M	Buy	25,074 +231	+0.9%	+$12.9K	0.84%	44
2014 Q3	$1.43M	Buy	24,843 +9,731	+64%	+$597K	0.94%	43
2014 Q2	$1.01M	Buy	15,112 +1,278	+9%	+$86.5K	0.7%	61
2014 Q1	$924K	Buy	+13,834	New	+$935K	0.65%	61

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Willingdon Wealth Management's GSK Position: Q1 2020 in Review

Willingdon Wealth Management sold out of GSK (GSK) in Q1 2020, closing a stake of 87 shares — an estimated $5K sold.

Willingdon Wealth Management first reported a position in GSK in Q1 2014 and held it in 16 quarters. The position peaked at $1.43M in Q3 2014. 817 funds tracked by Wall St. Rank hold GSK as of Q1 2020.

Willingdon Wealth Management reported no remaining GSK position as of Q1 2020 after selling out during the quarter.
Willingdon Wealth Management sold 87 GSK shares in Q1 2020, an estimated $5K.
Willingdon Wealth Management first reported a position in GSK in Q1 2014 and held it in 16 quarters.
Willingdon Wealth Management's GSK position peaked at $1.43M in Q3 2014.
817 funds tracked by Wall St. Rank held GSK as of Q1 2020.

Based on Willingdon Wealth Management's 13F filing for Q1 2020, filed 21 Apr 2020.